Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

著者: Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Façon, Cécile Sonntag, Jean Fontan, Laurent Garderet, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Pascal Lenain, Margaret Macro, Claire Mathiot, Frédérique Orsini‐Piocelle, Aurore Perrot, Anne‐Marie Stoppa, Niels W.C.J. van de Donk, Soraya Wuillème, Sonja Zweegman, Brigitte Kolb, Cyrille Touzeau, Murielle Roussel, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Jean Paul Fermand, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Sen Hong Zhuang, Christopher Chiu, Lixia Pei, Carla de Boer, Elena Smith, William Deraedt, Tobias Kampfenkel, Jordan M. Schecter, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet 2019 被引用: 953